Correction: Safety and efficacy of a freeze-dried trivalent antivenom for snakebites in the Brazilian Amazon: An open randomized controlled phase IIb clinical trial

Autor: Iran Mendonça-da-Silva, Marcus V. G. Lacerda, Antônio Magela Tavares, Wuelton Marcelo Monteiro, Jacqueline de Almeida Gonçalves Sachett, Maria Fátima Gomes Santos, José Felipe Jardim Sardinha, Lilian Zaparolli
Rok vydání: 2021
Předmět:
0301 basic medicine
Male
European People
Antivenom
RC955-962
Glycobiology
Snake Bites
Toxicology
Pathology and Laboratory Medicine
Biochemistry
Geographical locations
law.invention
Randomized controlled trial
law
Arctic medicine. Tropical medicine
Medicine and Health Sciences
Ethnicities
Toxins
Medicine
Bothrops
Snakebite
Prospective Studies
Prospective cohort study
Child
biology
Organic Compounds
Antivenins
lcsh:Public aspects of medicine
Middle Aged
Chemistry
Treatment Outcome
Infectious Diseases
Research Design
Anesthesia
Child
Preschool
Physical Sciences
Female
Public aspects of medicine
RA1-1270
Brazil
Research Article
Neglected Tropical Diseases
Adult
lcsh:Arctic medicine. Tropical medicine
Adolescent
lcsh:RC955-962
Clinical Research Design
Toxic Agents
Research and Analysis Methods
03 medical and health sciences
Young Adult
Adverse Reactions
Potency
Animals
Humans
Adverse effect
Blood Coagulation
Glycoproteins
Pharmacology
Venoms
business.industry
Organic Chemistry
Crotalus
Chemical Compounds
Infant
Newborn
Public Health
Environmental and Occupational Health
Biology and Life Sciences
Correction
Fibrinogen
Infant
lcsh:RA1-1270
South America
Tropical Diseases
Creatine
biology.organism_classification
Clinical trial
030104 developmental biology
Freeze Drying
Hemostasis
People and Places
Population Groupings
Adverse Events
business
Slavic People
Zdroj: PLoS Neglected Tropical Diseases, Vol 15, Iss 12 (2021)
PLoS Neglected Tropical Diseases
PLoS Neglected Tropical Diseases, Vol 11, Iss 11, p e0006068 (2017)
ISSN: 1935-2735
Popis: Background In tropical areas, a major concern regarding snakebites treatment effectiveness relates to the failure in liquid antivenom (AV) distribution due to the lack of an adequate cold chain in remote areas. To minimize this problem, freeze-drying has been suggested to improve AV stability. Methods and findings This study compares the safety and efficacy of a freeze-dried trivalent antivenom (FDTAV) and the standard liquid AV provided by the Brazilian Ministry of Health (SLAV) to treat Bothrops, Lachesis and Crotalus snakebites. This was a prospective, randomized, open, phase IIb trial, carried out from June 2005 to May 2008 in the Brazilian Amazon. Primary efficacy endpoints were the suppression of clinical manifestations and return of hemostasis and renal function markers to normal ranges within the first 24 hours of follow-up. Primary safety endpoint was the presence of early adverse reactions (EAR) in the first 24 hours after treatment. FDTAV thermal stability was determined by estimating AV potency over one year at 56°C. Of the patients recruited, 65 and 51 were assigned to FDTAV and SLAV groups, respectively. Only mild EARs were reported, and they were not different between groups. There were no differences in fibrinogen (p = 0.911) and clotting time (p = 0.982) recovery between FDTAV and SLAV treated groups for Bothrops snakebites. For Lachesis and Crotalus snakebites, coagulation parameters and creatine phosphokinase presented normal values 24 hours after AV therapy for both antivenoms. Conclusions/Significance Since promising results were observed for efficacy, safety and thermal stability, our results indicate that FDTAV is suitable for a larger phase III trial. Trial registration ISRCTNregistry: ISRCTN12845255; DOI: 10.1186/ISRCTN12845255 (http://www.isrctn.com/ISRCTN12845255).
Author summary Antivenoms (AV) are included in the WHO List of Essential Medicines, being the only treatment available for snakebites envenomings. In Brazil, five types of liquid snake AVs are distributed by the Ministry of Health for national use free of charge to patients. In remote areas, lack of an adequate cold chain impairs AV distribution to health facilities resulting in delay in patient care and, ultimately, in higher complication and case fatality rate. To minimize this problem, a freeze-drying process has been suggested to improve the stability of AVs, but freeze-dried AVs efficacy and safety evidence obtained from clinical trials is still very limited. Freeze-drying is a process by which water is removed from a sample without the need to apply heat. Benefits of lyophilization are: a) Samples are processed in aseptic conditions; b) Process does not use heat, ensuring formulation stability; c) Increases shelf life; d) Samples can be stored at room temperature for a long time; and e) Reduces weight and volume of samples, which is ideal for distribution. In this study, a freeze-dryed formulation is presented as a good alternative for a more stable trivalent antivenom in regions of the Amazon where high temperatures are common and the cold chain is poor. Our results suggest that such a product is adequate for a phase III trial.
Databáze: OpenAIRE
Externí odkaz: